贝伐单抗在肝癌治疗中的应用现状及进展

Bevacizumab: Current Approach in the Treatment of Hepatocellular Carcinoma

摘要: 随着肝癌生物疗法的不断发展，抗血管生成药–贝伐单抗已用于临床中晚期肝癌的分子靶向性治疗。贝伐单抗作为一种人工合成针对血管内皮生长因子(vascular endothelial growth factor ,VEGF)重组人源化单克隆IgG1抗体，可高效结合VEGF并防止其与肿瘤血管内皮细胞表面的受体(Flt-1和KDR)结合，进而精准抑制肿瘤血管内皮细胞增殖和肿瘤血管的新生。肝癌是一种预后较差的富血管性肿瘤，新生血管的形成与肝癌的发生发展有着密切的关系。大量临床实验(包括人体、动物和细胞水平实验)已经证实贝伐单抗及联合其他疗法靶向性治疗肝癌的有效性。本文将贝伐单抗用于肝癌治疗的应用现状及用于综合性介入治疗肝癌的可行性进行综述。 With the continuous development of biotherapy, anti-angiogenesis drug-bevacizumab has become clinical molecular targeted therapy for live cancer, a first-line treatment for patients with advanced hepatocellular carcinoma. Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant humanized monoclonal antibody that targets VEGF, it’s efficiently combination of VEGF can prevent VEGF combined with tumor vascular endothelial cell surface receptors (Flt-1 and KDR), thus inhibits cell proliferation and angiogenesis of the tumor. Hepatocellular carcinoma (HCC) is a vascular tumor with poor prognosis, and closely related to angiogenesis. Currently, numerous of studies confirmed the efficacy and tolerability of be-vacizumab in HCC. This review attempts to summarize the progress of bevacizumab in HCC and raises new possibilities of interventional therapy in the treatment of hepatocellular carcinoma with the help of Bevaci-zumab.